Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Clinical Genitourinary Cancer|November 27, 2024
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 StudyBrigida Anna Maiorano, Martina Catalano, Chiara Mercinelli, et al.
Journal of Translational Medicine|August 30, 2019
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final resultsGaetano Facchini, Sabrina Rossetti, Massimiliano Berretta, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2021
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trialOrazio Caffo, Cinzia Ortega, Franco Nolè, et al.
Cancer Immunology, Immunotherapy : CII|May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 studyMatteo Santoni, Zin W Myint, Thomas Büttner, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 studyPhilipp Mandel, Daniel Groener, Giulia Follacchio, et al.
European Urology Oncology|November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 StudyMatteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Cancers|January 8, 2020
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic FactorsMatteo Santoni, Daniel Y Heng, Sergio Bracarda, et al.
Targeted Oncology|October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> StudyOndřej Fiala, Francesco Massari, Umberto Basso, et al.
Targeted Oncology|June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 StudyMatteo Santoni, Francesco Massari, Zin W Myint, et al.
European Urology Oncology|July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Pageof 15